Insurance Stopped Covering Wegovy? What to Do Next — and What It Costs Now

If your insurance stopped covering Wegovy, first find out what changed: an expired approval, a denied renewal, a switched drug list, or a plan that dropped weight-loss drugs. Each needs a different next step. Talk to your prescriber before your next refill. NovoCare Pharmacy's standard cash prices: $349 per 4 standard pens; maintenance pill, $299 per 30 tablets.

The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.

On Medicare? The $50-a-month Medicare GLP-1 Bridge may help, but not if Part D already paid for a GLP-1 for you in 2026. Renewal denied after you lost weight? Some plans judge renewals on the weight you've lost since you started, not today's BMI, so ask which rule failed.

Here's the catch most people miss: an old approval with a future end date doesn't protect you if your plan dropped the benefit. The checklist below sorts out which one happened to you.

RX Index Decision Verdict: Start with your current prescriber and the exact written reason your coverage changed, then line up a way to pay so a paperwork fight doesn't turn into a long gap.

• Best for: Adults whose plan paid for Wegovy before and now rejects a refill or has sent a coverage-change notice.
• Not ideal for: People who never had coverage (see why insurance denies Wegovy). Anyone under 18, pregnant or planning a pregnancy, with type 1 diabetes or an active eating disorder, or told by a clinician not to use Wegovy should take this problem to their treating clinician first.
• The factor that matters most: Whether Wegovy is still a covered benefit on your plan. A valid prescription or an old approval doesn't settle that.

Insurance stopped covering Wegovy: what should I check first?

Check three things before you pick a fix: what the pharmacy said, when your old approval ends, and whether your plan still covers Wegovy at all. A rejected refill and a covered refill with a higher price need different next steps. The written reason from your plan tells you which path you're on.

A few words first, so the rest makes sense:

• Prior authorization (PA) is a permission slip from your insurer. The plan has to say yes before it pays.
• A formulary is your plan's list of covered drugs.
• A benefit exclusion is a plan rule that leaves a drug, or a use of a drug, out of coverage for everyone on the plan.
• A pharmacy benefit manager (PBM), such as CVS Caremark, Express Scripts, or OptumRx, runs prescription benefits for many plans.
• BMI, or body mass index, is a measure based on height and weight.

Step 1: Put your records side by side

Write down what you know. If something is missing, write "unknown" and ask for it. You don't have to guess before you make the first call.

Step 2: Match what you were told to the right request

This table is a guide to the right request. It isn't a ruling on your claim. Only your plan's written decision is.

Want to see it in action? Say you're 48, on the 2.4 mg pen through your employer, and HR says weight-loss drugs end January 1. That's the "weight-loss drugs are no longer covered" row: ask HR for the rule and any add-on coverage, and ask your doctor about a plan. If it stays uncovered, cash through NovoCare at today's price is $349 per box of 4 pens — $4,537 for 52 weeks if that price stays the same — and none of it counts toward your deductible. (That's a made-up example, not a real reader.)

The right next step isn't the same for everyone. It depends on your plan and its drug list, your state, your budget, whether you'd stay on the pen or consider the pill, and whether you'd only consider FDA-approved medicine. The RX Index's Find My GLP-1 Path tool is free, takes about 2 minutes, and needs no signup. Answer a few quick questions and see the GLP-1 paths and providers that fit your goals, budget, insurance, and situation. It won't tell you whether your plan will pay; only your plan can.

See which GLP-1 path fits you

Why did my insurance stop covering Wegovy?

Wegovy coverage can end for one of five reasons: the plan dropped weight-loss drugs, the plan switched its preferred drug, a renewal was denied, the approval lapsed, or the whole policy ended. Cost is one reason employers and insurers give for cutting the benefit. The exact words in your notice tell you which one you have.

You are far from alone. GoodRx, a drug-discount company, estimates that 27 million people with commercial insurance lacked Wegovy coverage as of July 2026 (GoodRx tracker, updated October 7, 2026).

Here's what that looks like in real plans:

• A plan-wide exclusion. Massachusetts' state employee plan (the Group Insurance Commission) stopped covering GLP-1s for weight loss on July 1, 2026. It kept diabetes coverage and allows requests for certain other uses, such as qualifying heart disease, obstructive sleep apnea, and MASH (a type of liver disease) (Mass.gov notice, June 8, 2026).
• An approval cut short. Blue Cross Blue Shield of Massachusetts said existing approvals on affected plans would end when the plan renewed in 2026, not on the date printed on the approval. Those drug lists also exclude the medicines for other approved uses. Some employers could buy continued coverage through a rider, an added benefit (BCBSMA provider fact sheet).
• An employer pulling back. Reuters reported on June 2 that Cigna would end GLP-1 weight-loss coverage for its own employees on July 1, 2026 (Reuters report).
• A drug-list change. CVS Caremark added Zepbound back to its commercial formularies as another preferred option on October 1, 2026 (CVS Health). Plans built on those lists can choose which drugs they keep.

The takeaway: the company on your card may manage claims while your employer chooses the benefits. Check your employer's plan design. See which employers have changed GLP-1 coverage.

What should I do before my next refill?

Send your prescriber your coverage notice, your next refill date, and the date of your last dose. If there could be a gap in treatment, ask for a plan before your next scheduled dose. Your prescriber decides what happens after a gap, not your insurer and not this page.

Here's why the date of your last dose matters. A gap can change the restart plan, and the Wegovy prescribing information has different instructions for injections and tablets. Ask your prescriber how to resume safely before restarting or switching forms.

That restart can also cost you. A lower standard pen dose doesn't have a lower standard price. It's $349 per box unless you meet a separate introductory offer's rules (more on that below).

Staying on treatment matters too. In the STEP 4 trial, adults who switched from Wegovy's dose of semaglutide to a placebo after 20 weeks regained an average of 6.9% of their week-20 body weight over the next 48 weeks. Those who stayed on it lost another 7.9% on average. Both groups had lifestyle support (JAMA, 2021). That trial was in adults with obesity or overweight without diabetes. It doesn't tell us what a short refill gap will do. More on what happens when you stop Wegovy.

Don't stretch, skip, or space out doses on your own to make a supply last. Call your prescriber.

Two scripts you can use today

To your insurer or PBM (the number on your card):

My plan paid for Wegovy before. Was this refill rejected, or covered with a higher cost to me? If it was rejected, what's the exact reason: an expired approval, a failed renewal, a drug no longer on the list, or a benefit that ended? Please send me the rule, the effective date, and the written decision. Does my old approval still apply? What does my prescriber need to send, where does it go, and what deadline or review rights apply? Can I have a reference number for this call?

To your prescriber (through the office's patient portal or usual secure message):

My Wegovy coverage changed. My next refill is due on [date], and my last dose was on [date]. I can send the pharmacy result, my old approval, and the plan's notice. Could your team check the reason and whether this needs a renewal, corrected records, or an appeal? Please include my treatment-start records if the plan asks for them. If there may be a gap, what's my care plan before my next dose? I'd also like to talk about what I can afford if the plan won't pay.

Write down who you talked to, the date, the reference number, and what they promised. Written answers beat phone promises.

Can I get my Wegovy coverage back?

You can sometimes get Wegovy coverage back. It depends on why payment stopped. An expired approval or a missing record can often be fixed with a renewal. A drug-list switch may be fixed with a formulary exception. A plan-wide exclusion usually can't be reversed by proving you need the drug, but you can still ask whether the rule was applied to you correctly.

If your approval expired or your renewal was denied

Ask for the plan's current continuation criteria (the rules for staying on a drug) and the exact rule your request failed. Missing records and not meeting a rule are different problems with different fixes.

Your prescriber should answer the plan's rule point by point, with your starting weight, current weight, percent lost, and dose history. NovoCare notes that a PA can last anywhere from 30 days to more than a year, so know your renewal date (NovoCare). For the difference between first approvals and renewals, see initial vs. renewal prior authorization. To challenge a decision, use our step-by-step Wegovy appeal guide and the free GLP-1 appeal letter template.

If your BMI is lower now

Your current BMI alone doesn't tell you whether you meet your plan's renewal rules. Some plans judge renewals on how you've responded since you started, not on whether you'd qualify as a brand-new patient.

Here's one real example. Aetna's 2026 Wegovy policy for adults using it for weight loss asks, for continuing therapy, that you've been on a stable maintenance dose for at least 3 months and have lost at least 5% of your starting weight, or kept off that first 5%, with records to prove it (Aetna policy 4774-C). That's one insurer's rule. Your plan's rule is the one that counts, so ask for it in writing.

If the plan dropped the benefit, or your old approval still has time left

An approval with a future end date doesn't guarantee another paid refill after a benefit change. In the BCBSMA example above, approvals on affected plans ended at plan renewal. A medical-need argument alone doesn't add a benefit the plan excludes; ask whether the rule applies to you and what review rights remain.

What you can still do:

• Ask the plan to show the exact rule, which plan or group it covers, and when it starts.
• Ask your employer whether it bought add-on coverage or allows any exception. NovoCare offers a sample coverage request letter your doctor can adapt on their letterhead for you to take to HR. Our guide on asking your employer to cover GLP-1s has more.
• Ask your doctor whether a covered use truly applies to you. Wegovy is FDA-approved to lower the risk of heart attack, stroke, and heart-related death in adults with known heart disease and obesity or overweight, and some plans that exclude weight loss allow requests for that use (Wegovy label; Mass. GIC). That's a diagnosis your doctor has to document, never a billing trick. See Wegovy for heart disease.
• If the plan only switched its preferred drug, ask about a formulary exception, or ask your prescriber whether the drug your plan prefers fits you. See switching from Wegovy to Zepbound.

The difference between an exclusion and a PA denial is laid out in plan exclusion vs. prior authorization.

Did your plan have to warn you?

Notice rules can apply, but the timing depends on the rule and the kind of plan. For employer plans covered by ERISA, a federal benefits law, the usual deadline for a summary of a major benefit cut is 60 days after adoption. A separate rule requires 60 days' advance notice for certain changes outside renewal that affect the Summary of Benefits and Coverage (SBC).

The details, in plain words:

• After-the-fact notice (ERISA): Employer plans covered by ERISA must send a summary of a "material reduction" in benefits within 60 days after adopting it. Plans that send updates on a regular cycle of 90 days or less can use that cycle instead (29 CFR 2520.104b-3).
• Advance notice for changes outside renewal: A material change that affects the SBC, isn't reflected in the latest SBC, and happens outside renewal or reissuance must be announced at least 60 days before it takes effect (29 CFR 2590.715-2715). Whether a GLP-1 change triggers this depends on what your plan's summary says.

What to do: email HR or your plan administrator and ask for your Summary Plan Description, the notice of the change, and whether the plan is self-funded (the employer pays claims itself) or fully insured (the employer buys an insurance policy). In the same email, ask whether a one-time transition refill is available. It's worth asking, but not guaranteed. Fully insured plans may also follow state rules, so your state insurance department can help. This is general information, not legal advice.

Does my insurance type change the next step?

Your insurance type changes who handles a Wegovy coverage loss and which rules apply. An insurer's brand name alone doesn't tell you the rules. Use the program that actually covers you.

Employer, Marketplace, or individual plans

For employer coverage, start with the notice and HR steps above. For Marketplace or individual coverage, ask the insurer for the rule and review process. If your whole job-based plan ended, ask about COBRA, which can let you keep that group plan for a time, and new coverage. Losing qualifying job-based coverage generally gives you 60 days before and 60 days after the loss to pick a Marketplace plan outside open enrollment. Losing coverage for one drug doesn't create that enrollment window (HealthCare.gov). See does COBRA cover Wegovy.

Medicare

Medicare's GLP-1 Bridge charges eligible people a $50 copay per fill for any Wegovy pen or pill dose prescribed for weight loss. It runs from July 1, 2026, through December 31, 2027. CMS looks at your BMI from when you first started a GLP-1, even if that was before you had Medicare (CMS).

That $50 does not count toward your Part D out-of-pocket limit, and Part D's low-income subsidy does not lower it (CMS Part D guidance).

To qualify, you must be 18 or older and have an eligible Part D plan. This includes standalone Part D and Medicare Advantage HMO or PPO plans with drug coverage; CMS lists the eligible plan types and exceptions. Your prescriber must request prior approval and confirm ongoing nutrition and activity support. When you first started a GLP-1, you also needed one of these:

Two big exceptions:

• If Part D already paid for a GLP-1 for you in 2026, including an employer or union's supplemental Part D benefit, you can't use the Bridge in 2026 (CMS Part D guidance).
• If you have type 2 diabetes, moderate-to-severe obstructive sleep apnea, or MASH without cirrhosis but with moderate-to-advanced liver scarring (F2–F3), the Bridge isn't for you. Those diagnoses go through your regular Part D plan. Your prescriber must confirm whether a diagnosis applies.

For 2027, CMS has not yet said how far back it will check past GLP-1 use (CMS Part D guidance).

There's no formal appeal inside the Bridge, but your prescriber can resubmit the form with corrected or new information. That doesn't remove your regular Part D appeal rights. If Wegovy is prescribed to lower the risk of major heart-related events, CMS says to use your regular Part D plan, even if weight loss is also a goal (CMS).

Say you turned 65 in September. You started Wegovy in 2024 at a BMI of 37, and it's 33 now. Your employer plan paid until you left. Under CMS's rule, your prescriber attests to the 37. That meets the BMI part of the rule, not every requirement for approval. (Hypothetical example.) More detail: Medicare GLP-1 Bridge eligibility.

Medicaid

Medicaid coverage of Wegovy for weight loss depends on your state, and several states have cut it. Some states keep coverage for other uses or certain members, so read your state's own notice and follow its hearing instructions if you disagree (California's member notice; South Carolina plan notice; Pennsylvania notice). Check GLP-1 Medicaid coverage by state.

If you have both Medicare and Medicaid, check the Medicare section too. CMS allows people with both to use the Bridge if they meet its Part D and clinical rules (CMS).

If you pay cash, NovoCare Pharmacy accepts people with government insurance who choose to pay out of pocket (NovoCare Pharmacy terms). The $25 savings offer does not apply to government plans. Ro doesn't currently accept Medicaid members (Ro).

If it stays uncovered, what will my next refill cost?

Price the prescription you're on now, not a starter deal. As of October 17, 2026, NovoCare Pharmacy charges $349 per box of 4 Wegovy pens (a 28-day supply) for every dose from 0.25 mg to 2.4 mg, $399 for the Wegovy HD 7.2 mg pen, and $149 to $299 for a 30-day bottle of pills. These prices are for the medicine only.

Totals assume today's prices stay the same. Thirteen boxes cover 52 weeks (364 days); 12 bottles cover 360 days. These are medicine-only comparisons, not calendar-year bills, and exclude introductory offers and care fees.

Source: NovoCare Pharmacy Wegovy prices and terms, checked October 17, 2026. Delivery is free. Your current prescriber can send your prescription there whether you're new to Wegovy or already taking it.

Read the fine print before you count on a lower number:

The $199 pen price has two different sets of rules. Both limit it to a maximum of two qualifying 28-day fills of 0.25 mg or 0.5 mg pens. The program decides whether you qualify; having taken Wegovy before doesn't answer that by itself.

Sources: NovoCare Pharmacy terms and Wegovy savings-offer terms. The ordinary 4 mg pill price is also $199; it is separate from these pen offers.

• The $25 savings card needs commercial insurance that covers Wegovy. It can lower what you pay to as little as $25, with a maximum saving of $100 per 28-day pen supply or 30-day pill supply. Government plans are excluded. It won't make an uncovered refill $25 (savings-offer terms).
• Cash doesn't count toward your deductible. NovoCare's terms say you can't count self-pay costs toward your deductible or out-of-pocket limit, or ask your insurer to pay you back (NovoCare Pharmacy terms).
• The sticker price isn't the whole receipt. Ask your prescriber's office about visit, lab, or other fees. An unknown fee isn't a $0 fee.
• HD pens: Check coverage for the exact 7.2 mg product. The $399 is its self-pay price, not proof that every plan excludes it. Aetna's published policy includes HD, and CMS lists it in the Bridge (Aetna; CMS).

Could the pill save money? At the top dose it's $299 for 30 days versus $349 for 28 days on the pen. But the pill has its own label instructions, including separate switching guidance, and whether and how you'd switch is your prescriber's call. See Wegovy pill vs. injection. For every other way to pay, see the cheapest ways to get Wegovy without insurance.

NovoCare Pharmacy says it accepts HSA/FSA cards and funds; confirm your account's rules before paying (pharmacy FAQ). Other routes have their own terms; see Wegovy providers that take HSA or FSA.

If even this is out of reach, tell your prescriber your real monthly limit. That gives your prescriber a real budget to work with.

Do I need a new provider?

You usually don't need a new Wegovy provider to start. Your current prescriber can request a renewal, send records, and send your prescription to NovoCare Pharmacy. A new provider can't make an excluded benefit covered. A new provider makes sense if your doctor won't handle the paperwork, doesn't offer ongoing GLP-1 care, or you want ongoing check-ins.

Ro fits two kinds of readers here: people with commercial insurance whose plan still covers some GLP-1s and who want someone else to handle the prior authorization, and people paying cash who need a prescriber.

Ro's free insurance check gives you a coverage report for the Wegovy pen, Zepbound autoinjector pen, and Ozempic pen. It asks for contact and insurance details; it doesn't submit a prior authorization or write a prescription. It doesn't check the Wegovy pill. Paid Ro care includes insurance coordination for supported pens after a prescription; Ro estimates 1–3 weeks for that process (Ro). For cash pay, Ro says its Wegovy prices match NovoCare's.

The honest catches:

• Ro doesn't fix exclusions. If your plan dropped weight-loss drugs entirely, no paperwork changes that.
• Ro doesn't accept Medicaid members for treatment, and it offers Medicare and TRICARE members cash-pay treatment only, not insurance help.
• Care is a paid membership, billed separately from medicine. Ro advertises $39 for the first month (refunded if you're not eligible for GLP-1 treatment), then $149 a month on the monthly plan. After the first month, its annual option works out to $74 a month, paid as $888 for a 12-month term. That is a prepaid amount, not a $74 monthly bill. On the monthly plan, the first 12 months of membership come to $1,678, plus medicine (Ro pricing). Confirm your selected plan's amount and billing date before enrolling.
• Cancel at least 48 hours before renewal to avoid the next charge. Apart from the stated first-month eligibility refund, Ro's terms say paid membership fees are nonrefundable. Membership can keep renewing even when you don't receive medication. Ro also charges $15 per consult after 24 in a year, and additional lab tests are priced separately (Ro terms).

So here's the line: if you already have a doctor who'll keep prescribing, go straight to NovoCare and skip the membership. If you need a prescriber or want someone to chase the insurance paperwork on a drug your plan still covers, Ro is a solid option to review. More on whether Ro appeals GLP-1 denials.

Need help finding out what your plan covers? Ro's free check gives you a coverage report for supported pens. Prescribing care is separate and carries the membership fees above. A report is not an approval.

Check your coverage with Ro

What about compounded semaglutide?

Compounded semaglutide is not Wegovy and is not FDA-approved. The FDA doesn't review compounded drugs for safety, effectiveness, or quality before they reach patients. The FDA says compounding may be appropriate when a patient's medical need can't be met by an FDA-approved drug (FDA).

A few facts to know before you consider it:

• The FDA declared the semaglutide shortage over on February 21, 2025. The shortage-based grace periods ended in 2025. FDA's current policy restricts routine copies of drugs that are commercially available; a patient-specific prescription must still meet the compounding rules (FDA).
• The FDA has received reports of dosing errors with compounded semaglutide and has warned about fake products with false labels (FDA).
• Wegovy's clinical evidence, including STEP 4 above, does not establish the safety or effectiveness of a particular compounded product.

If your clinician identifies a medical need that an FDA-approved drug can't meet and recommends considering a compounded prescription, read our Embody review first. Price alone doesn't establish that medical need. Embody offers cash-pay compounded semaglutide injections with clinician review (Embody). We haven't verified a current total you would owe. Before paying, confirm the exact amount due today, the plan length, the renewal and refund terms, the dispensing pharmacy, and whether it serves your state. Also see our compounded GLP-1 decision guide.

See Embody's current pricing

How we checked this page

On October 17, 2026, we read the sources linked on this page: NovoCare's price pages and pharmacy terms, the Wegovy prescribing information, CMS's Medicare GLP-1 Bridge pages, the federal notice rules, Aetna's and BCBSMA's published policies, Ro's pricing, free-check, insurance, and terms pages, Embody's published offering, and the FDA's compounding pages. We built the tables from those sources.

Learn how we assess providers and treatment paths.

What we actually verified (October 17, 2026) | What we checked | What it confirms | What it can't tell you | |---|---|---| | NovoCare Pharmacy prices, terms, and savings-offer fine print | Medicine prices, supply sizes, the $199 and $25 rules, free delivery, no deductible credit | Your prescriber's fees or your final charge | | Wegovy prescribing information, revised June 2026 | Labeled forms, uses, and different missed-dose and switching instructions | What your prescriber will decide for you | | CMS Medicare GLP-1 Bridge pages | Dates, $50 copay, eligibility rules, the 2026 Part D exclusion | Whether CMS approves you | | Aetna, BCBSMA, Mass. GIC published rules | How those named plans handle renewals and exclusions | Your plan's rules | | Federal notice rules (29 CFR) | ERISA benefit-cut notices and the separate SBC advance-notice rule | Whether a rule covers your plan or your plan followed it | | Ro pricing, free check, insurance, and terms pages | Advertised fees, refunds, renewals, and service scope (provider-stated) | Your exact checkout terms, approval odds, or your experience | | FDA compounding pages | The FDA's published position | Whether any specific compounded product is safe or legal | We did not see your plan's decision, test any provider, or verify Embody's current checkout total.

Questions about losing Wegovy coverage

Can I keep getting Wegovy if my insurance won't pay anymore?

Yes, if your prescriber keeps prescribing it and you find a way to pay. Ask your current doctor to fix anything fixable first, then to send your prescription to NovoCare Pharmacy if you'll pay cash. If cost is the problem, tell your prescriber your real budget so you can plan together.

What's the cheapest way to stay on Wegovy without insurance?

As of October 17, 2026, NovoCare Pharmacy charges $349 per box of 4 pens for 0.25–2.4 mg doses, $399 for HD 7.2 mg pens, and $299 for a 30-day bottle of the 25 mg pill, with free delivery and no pharmacy membership fee. If you're on Medicare and eligible, the GLP-1 Bridge charges $50 per fill. A switch to the pill is a decision for your prescriber, not just a price choice.

Are there exceptions if my employer stopped covering weight-loss drugs?

Ask for the exact rule and whether your employer bought add-on coverage or allows exceptions. An appeal arguing you need the drug usually won't add back an excluded benefit, but you can ask whether the rule was applied to you correctly. If you have a covered condition, such as heart disease, your doctor can request coverage for that use.

Did losing weight make me ineligible for renewal?

You can't tell from your current BMI alone. Some plans judge renewals on your response since starting, not today's BMI. Aetna's 2026 adult weight-loss renewal rule, for example, looks for at least 5% weight loss from your start, or keeping it off, after 3 months on a stable maintenance dose. Ask which rule failed and make sure your starting records were sent.

Does an approval with a future end date guarantee another covered refill?

No. A benefit change can end coverage before the date on your approval. BCBSMA's 2026 change ended approvals at plan renewal. Ask your plan what changed and when.

Can I still use the $25 savings card or the $199 price?

The $25 offer needs commercial insurance that covers Wegovy; government plans are excluded. The $199 pen offer is limited to at most two qualifying 0.25 mg or 0.5 mg fills. NovoCare Pharmacy requires no previous Wegovy injection fill through its current or Legacy pharmacy, with the prescription written and received by December 31, 2026, and shipped by January 31, 2027. The retail offer instead requires no Wegovy injection savings-offer redemption in the previous 365 days, with redemption and filling by December 31, 2026 (pharmacy terms; savings-offer terms). The standard 0.25–2.4 mg pen price is $349 per box.

Will my insurance pay me back if I pay cash and later win an appeal?

Don't count on it. NovoCare Pharmacy's terms say self-pay purchases can't be sent to your insurer for repayment or counted toward your deductible. If you buy somewhere else, ask the plan and pharmacy about their rules before you pay.

Can Medicare's $50 Bridge replace coverage that stopped?

Only if you qualify. You must be 18 or older, have an eligible Part D plan, and meet the starting-BMI and other criteria above, with prior approval. If Part D already paid for a GLP-1 for you in 2026, you can't use the Bridge in 2026. Type 2 diabetes, moderate-to-severe obstructive sleep apnea, and MASH without cirrhosis but with F2–F3 liver scarring also route through regular Part D. For 2027, CMS has not yet said how far back it will check past GLP-1 use.

What if I miss doses while I sort this out?

Tell your prescriber the date of your last dose and when your next refill might come. A gap can change the restart plan, and the label has different instructions for injections and tablets. Your prescriber decides how to resume; don't change your doses on your own.

Is compounded semaglutide the same as Wegovy?

No. Compounded drugs are not FDA-approved, and the FDA doesn't review them for safety, effectiveness, or quality before they reach patients. Wegovy's studies do not establish the safety or effectiveness of a particular compounded product.

Sources

Source text checked October 17, 2026. Separate publication, data, and policy dates are shown below.

• NovoCare Pharmacy, Wegovy prices and terms
• NovoCare, Wegovy coverage FAQ
• NovoCare, Pharmacy terms and conditions and Wegovy savings-offer terms
• Novo Nordisk, Wegovy prescribing information (revised June 2026)
• NovoCare, Sample coverage request letter (June 2021)
• CMS, Medicare GLP-1 Bridge: Information for Providers
• CMS, Medicare GLP-1 Bridge: Information for Part D Plans
• eCFR, 29 CFR 2520.104b-3
• eCFR, 29 CFR 2590.715-2715
• HealthCare.gov, Special Enrollment Period
• Medi-Cal Rx, GLP-1 coverage changes (effective January 1, 2026); Select Health of South Carolina, Prescription benefits (January 1, 2026 change); Pennsylvania DHS, GLP-1 coverage notice (published December 27, 2025)
• Aetna, Wegovy PA with Limit 4774-C, 2026
• Blue Cross Blue Shield of Massachusetts, GLP-1 provider fact sheet (2026 renewal changes)
• Massachusetts Group Insurance Commission, GLP-1 coverage update (June 8, 2026)
• CVS Health, CVS Caremark GLP-1 coverage options (May 28, 2026)
• Reuters, Cigna drops GLP-1 coverage for its own employees (June 2, 2026)
• GoodRx, Insurance coverage tracker for GLP-1s (updated October 7, 2026; July 2026 data)
• Rubino D et al., STEP 4 trial, JAMA 2021
• Ro, Pricing, Free insurance check, Insurance, and Terms of use
• Embody, Published offering and Terms
• FDA, Concerns with unapproved GLP-1 drugs used for weight loss
• FDA, Policies for compounders as GLP-1 supply stabilizes (April 1, 2026 policy update; shortage resolved February 21, 2025)

Still not sure which GLP-1 path fits you? Take The RX Index's free Find My GLP-1 Path quiz — about 2 minutes, no signup.